← Back to patent-cliff list
MAX-10181
Tier C — Watch / tradeMAX-10181
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PD-L1, PD-1
Indications (approved)：Glioma, Solid tumour, Glioblastoma
Regional status
US
-
EU
-
China
Phase II
2024-09-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MAX-10181?
Approved indications include: Glioma, Solid tumour, Glioblastoma.
When does the MAX-10181 patent expire?
No public expiry year is available for MAX-10181 yet; this page updates once verified.
How do I get a quote for MAX-10181 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01